Related Experiment Videos
Levamisole and interferon in children with chronic hepatitis B
M Ruiz-Moreno1, R García, M J Rua
1Department of Pediatrics, Autónoma University, Fundación Jimenez Diaz, Madrid, Spain.
Hepatology (Baltimore, Md.)
|August 1, 1993
Summary
Adding levamisole to interferon therapy for chronic hepatitis B in children did not improve outcomes. This combination also led to more severe side effects compared to interferon alone.
Area of Science:
- Hepatology
- Immunology
- Pediatric Gastroenterology
Background:
- Chronic hepatitis B virus (HBV) infection remains a significant global health concern in children.
- Interferon-alpha-2a is a recognized treatment for chronic hepatitis B, but its efficacy can be limited.
- Levamisole, an immunomodulatory agent, has been explored as an adjunct therapy in various conditions.
Purpose of the Study:
- To investigate the efficacy and safety of combining levamisole with interferon-alpha-2a in children with chronic hepatitis B.
- To determine if the combination therapy offers superior virological and biochemical responses compared to interferon alone.
Main Methods:
- A randomized trial involving 38 children with chronic hepatitis B.
- Group 1 received interferon-alpha-2a alone for 6 months.
- Group 2 received levamisole concurrently with interferon-alpha-2a for 6 months, with levamisole administered for 45 days.
Main Results:
- No significant differences were observed in the loss of hepatitis B virus DNA, HBeAg, or normalization of ALT levels between the two groups.
- Both groups showed an increase in ALT and soluble interleukin-2 receptor levels during therapy, with a more pronounced increase in the combination group.
- The combination of levamisole and interferon was associated with severe adverse events.
Conclusions:
- Simultaneous administration of levamisole and interferon-alpha-2a does not enhance the therapeutic benefits of interferon alone in children with chronic hepatitis B.
- The combination therapy is linked to increased toxicity and severe side effects, making it less favorable.
- Further research may be needed to explore alternative or optimized combination strategies for chronic hepatitis B management in pediatric populations.